Interfering with Tumor Hypoxia for Radiotherapy Optimization

1.

Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70. https://doi.org/10.1016/S0092-8674(00)81683-9.CrossRefPubMed

2.

Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144(5):646–74. https://doi.org/10.1016/j.cell.2011.02.013.CrossRefPubMed

3.

Nagy JA, Chang S-H, Shih S-C, Dvorak AM, Dvorak HF. Heterogeneity of the tumor vasculature. Semin Thromb Hemost. 2010;36(03):321–31. https://doi.org/10.1055/s-0030-1253454.CrossRefPubMedPubMedCentral

4.

Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev. 2005;15(1):102–11. https://doi.org/10.1016/j.gde.2004.12.005.CrossRefPubMed

5.

Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11(6):393–410. https://doi.org/10.1038/nrc3064.CrossRefPubMed

6.

Harris AL. Hypoxia — a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2(1):38–47. https://doi.org/10.1038/nrc704.CrossRefPubMed

7.

Bhandari V, Hoey C, Liu LY, Lalonde E, Ray J, Livingstone J, et al. Molecular landmarks of tumor hypoxia across cancer types. Nat Genet. 2019;51(2):308–18. https://doi.org/10.1038/s41588-018-0318-2.CrossRefPubMed

8.

Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 1955;9(4):539–49. https://doi.org/10.1038/bjc.1955.55.CrossRefPubMedPubMedCentral

9.

Vaupel P, Kelleher DK, Höckel M. Oxygenation status of malignant tumors: Pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol. 2001;28(2 Suppl 8):29–35. https://doi.org/10.1016/S0093-7754(01)90210-6.CrossRefPubMed

10.

Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors. Med Oncol. 2001;18(4):243–59. https://doi.org/10.1385/MO:18:4:243.CrossRefPubMed

11.

Nordsmark M, Alsner J, Keller J, Nielsen OS, Jensen OM, Horsman MR, et al. Hypoxia in human soft tissue sarcomas: Adverse impact on survival and no association with p53 mutations. Br J Cancer. 2001;84(8):1070–5. https://doi.org/10.1054/bjoc.2001.1728.CrossRefPubMedPubMedCentral

12.

Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol. 2005;77(1):18–24. https://doi.org/10.1016/j.radonc.2005.06.038.CrossRefPubMed

13.

Brown JM. Tumor hypoxia in cancer therapy. Methods Enzymol. 2007;435:295–321. https://doi.org/10.1016/S0076-6879(07)35015-5.CrossRef

14.

Dhani N, Fyles A, Hedley D, Milosevic M. The clinical significance of hypoxia in human cancers. Semin Nucl Med. 2015;45(2):110–21. https://doi.org/10.1053/j.semnuclmed.2014.11.002.CrossRefPubMed

15.

Bhandari V, Li CH, Bristow RG, Boutros PC. Divergent mutational processes distinguish hypoxic and normoxic tumours. Nat Commun. 2020;11(1):737. https://doi.org/10.1038/s41467-019-14052-x.CrossRefPubMedPubMedCentral

16.

Vaupel P. Prognostic potential of the pretherapeutic tumor oxygenation status. Adv Exp Med Biol. 2009;645:241–6. https://doi.org/10.1007/978-0-387-85998-9_36.CrossRefPubMed

17.

Höckel M, Knoop C, Schlenger K, Vorndran B, Bauβnann E, Mitze M, et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol. 1993;26(1):45–50. https://doi.org/10.1016/0167-8140(93)90025-4.CrossRefPubMed

18.

Richards CH, Mohammed Z, Qayyum T, Horgan PG, McMillan DC. The prognostic value of histological tumor necrosis in solid organ malignant disease: a systematic review. Future Oncol. 2011;7(10):1223–35. https://doi.org/10.2217/fon.11.99.CrossRefPubMed

19.

Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer. 2008;8(3):180–92. https://doi.org/10.1038/nrc2344.CrossRefPubMed

20.

Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang L-P, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T reg cells. Nature. 2011;475(7355):226–30. https://doi.org/10.1038/nature10169.CrossRefPubMed

21.

Noman MZ, Hasmim M, Messai Y, Terry S, Kieda C, Janji B, et al. Hypoxia: a key player in antitumor immune response. A Review in the theme: Cellular responses to hypoxia. Am J Physiol-Cell Physiol. 2015;309(9):C569–79. https://doi.org/10.1152/ajpcell.00207.2015.CrossRefPubMedPubMedCentral

22.

Rankin EB, Giaccia AJ. Hypoxic control of metastasis. Science. 2016;352(6282):175–80. https://doi.org/10.1126/science.aaf4405.CrossRefPubMedPubMedCentral

23.

Grau C, Overgaard J. Effect of etoposide, carmustine, vincristine, 5-fluorouracil, or methotrexate on radiobiologically oxic and hypoxic cells in a C3H mouse mammary carcinoma in situ. Cancer Chemother Pharmacol. 1992;30(4):277–80. https://doi.org/10.1007/BF00686295.CrossRefPubMed

24.

Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer. 2008;8(6):425–37. https://doi.org/10.1038/nrc2397.CrossRefPubMedPubMedCentral

25.

Wenger RH, Kurtcuoglu V, Scholz CC, Marti HH, Hoogewijs D. Frequently asked questions in hypoxia research. Hypoxia. 2015;3:35–43. DOI. https://doi.org/10.2147/HP.S92198.CrossRefPubMedPubMedCentral

26.

Rey S, Schito L, Koritzinsky M, Wouters BG. Molecular targeting of hypoxia in radiotherapy. Adv Drug Deliv Rev. 2017;109:45–62. https://doi.org/10.1016/j.addr.2016.10.002.CrossRefPubMed

27.

Mortensen LS, Buus S, Nordsmark M, Bentzen L, Munk OL, Keiding S, et al. Identifying hypoxia in human tumors: A correlation study between 18F-FMISO PET and the Eppendorf oxygen-sensitive electrode. Acta Oncol Stockh Swed. 2010;49(7):934–40. https://doi.org/10.3109/0284186X.2010.516274.CrossRef

28.

Bayer C, Shi K, Astner ST, Maftei C-A, Vaupel P. Acute versus chronic hypoxia: Why a simplified classification is simply not enough. Int J Radiat Oncol Biol Phys. 2011;80(4):965–8. https://doi.org/10.1016/j.ijrobp.2011.02.049.CrossRefPubMed

29.

Hall EJ, Giaccia AJ. Radiobiology for the radiologist. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2012.

30.

Crabtree HG, Cramer W, Murray JA. The action of radium on cancer cells. II.—Some factors determining the susceptibility of cancer cells to radium. Proc R Soc Lond Ser B Contain Pap Biol Character. 1933;113(782):238–50. https://doi.org/10.1098/rspb.1933.0044.CrossRef

31.

Gray LH, Conger AD, Ebert M, Hornsey S, Scott OCA. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 1953;26(312):638–48. https://doi.org/10.1259/0007-1285-26-312-638.CrossRefPubMed

32.

Joiner MC, van der Kogel AJ, van der Kogel AJ. Basic clinical radiobiology. Boca Raton, FL: CRC Press; 2018. https://doi.org/10.1201/9780429490606.CrossRef

33.

Wouters BG, Brown JM. Cells at intermediate oxygen levels can be more important than the “hypoxic fraction” in determining tumor response to fractionated radiotherapy. Radiat Res. 1997;147(5):541–50. https://doi.org/10.2307/3579620.CrossRefPubMed

34.

Wenger RH. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J. 2002;16(10):1151–62. https://doi.org/10.1096/fj.01-0944rev.CrossRefPubMed

35.

Lee P, Chandel NS, Simon MC. Cellular adaptation to hypoxia through hypoxia inducible factors and beyond. Nat Rev Mol Cell Biol. 2020;21(5):268–83. https://doi.org/10.1038/s41580-020-0227-y.CrossRefPubMedPubMedCentral

36.

Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992;12(12):5447–54. https://doi.org/10.1128/MCB.12.12.5447.CrossRefPubMedPubMedCentral

37.

Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359(6398):843–5. https://doi.org/10.1038/359843a0.CrossRefPubMed

38.

Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, et al. Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest. 2002;110(7):993–1002. https://doi.org/10.1172/JCI15337.CrossRefPubMedPubMedCentral

39.

Bodi I, Bishopric NH, Discher DJ, Wu X, Webster KA. Cell-specificity and signaling pathway of endothelin-1 gene regulation by hypoxia. Cardiovasc Res. 1995;30(6):975–84. https://doi.org/10.1016/S0008-6363(95)00164-6.CrossRefPubMed

40.

Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem. 1994;269(38):23757–63. https://doi.org/10.1016/S0021-9258(17)31580-6.CrossRefPubMed

41.

Semenza GL. Oxygen-dependent regulation of mitochondrial respiration by hypoxia-inducible factor 1. Biochem J. 2007;405(1):1–9. https://doi.org/10.1042/BJ20070389.CrossRefPubMed

42.

Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol. 2004;14(3):198–206. https://doi.org/10.1016/j.semradonc.2004.04.008.CrossRefPubMed

43.

Goda N, Ryan HE, Khadivi B, McNulty W, Rickert RC, Johnson RS. Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol Cell Biol. 2003;23(1):359–69. https://doi.org/10.1128/mcb.23.1.359-369.2003.CrossRefPubMedPubMedCentral

44.

Hackenbeck T, Knaup KX, Schietke R, Schödel J, Willam C, Wu X, et al. HIF-1 or HIF-2 induction is sufficient to achieve cell cycle arrest in NIH3T3 mouse fibroblasts independent from hypoxia. Cell Cycle. 2009;8(9):1386–95. https://doi.org/10.4161/cc.8.9.8306.CrossRefPubMed

45.

Carmeliet P, Dor Y, Herbert J-M, Fukumura D, Brusselmans K, Dewerchin M, et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 1998;394(6692):485–90. https://doi.org/10.1038/28867.CrossRefPubMed

46.

Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996;379(6560):88–91. https://doi.org/10.1038/379088a0.CrossRefPubMed

47.

Vaupel P. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist. 2008;13(S3):21–6. https://doi.org/10.1634/theoncologist.13-S3-21.CrossRefPubMed

48.

Seimiya H, Tanji M, Oh-hara T, Tomida A, Naasani I, Tsuruo T. Hypoxia up-regulates telomerase activity via mitogen-activated protein kinase signaling in human solid tumor cells. Biochem Biophys Res Commun. 1999;260(2):365–70. https://doi.org/10.1006/bbrc.1999.0910.CrossRefPubMed

49.

Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell. 2007;129(3):465–72. https://doi.org/10.1016/j.cell.2007.04.019.CrossRefPubMedPubMedCentral

50.

Luo W, Wang Y. Hypoxia mediates tumor malignancy and therapy resistance. Adv Exp Med Biol. 2019;1136:1–18. https://doi.org/10.1007/978-3-030-12734-3_1.CrossRefPubMed

51.

Sørensen BS, Horsman MR. Tumor hypoxia: Impact on radiation therapy and molecular pathways. Front Oncol. 2020;10:562. https://doi.org/10.3389/fonc.2020.00562.CrossRefPubMedPubMedCentral

52.

Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci. 1993;90(9):4304–8. https://doi.org/10.1073/pnas.90.9.4304.CrossRefPubMedPubMedCentral

53.

Wang GL, Semenza GL. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem. 1993;268(29):21513–8. https://doi.org/10.1016/S0021-9258(20)80571-7.CrossRefPubMed

54.

Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci. 1995;92(12):5510–4. https://doi.org/10.1073/pnas.92.12.5510.CrossRefPubMedPubMedCentral

55.

Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1α. Genes Dev. 1998;12(2):149–62. https://doi.org/10.1101/gad.12.2.149.CrossRefPubMedPubMedCentral

56.

Wenger RH, Stiehl DP, Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci STKE. 2005;2005:re12. https://doi.org/10.1126/stke.3062005re12.CrossRefPubMed

57.

Wang GL, Semenza GL. Molecular basis of hypoxia-induced erythropoietin expression. Curr Opin Hematol. 1996;3(2):156–62. https://doi.org/10.1097/00062752-199603020-00009.CrossRefPubMed

58.

Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFα targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science. 2001;292(5516):464–8. https://doi.org/10.1126/science.1059817.CrossRefPubMed

59.

Jaakkola P, Mole DR, Tian Y-M, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292(5516):468–72. https://doi.org/10.1126/science.1059796.CrossRefPubMed

60.

Kaelin WG, Ratcliffe PJ. Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway. Mol Cell. 2008;30(4):393–402. https://doi.org/10.1016/j.molcel.2008.04.009.CrossRefPubMed

61.

Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148(3):399–408. https://doi.org/10.1016/j.cell.2012.01.021.CrossRefPubMedPubMedCentral

62.

Mole DR, Blancher C, Copley RR, Pollard PJ, Gleadle JM, Ragoussis J, et al. Genome-wide association of hypoxia-inducible factor (HIF)-1α and HIF-2α DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem. 2009;284(25):16767–75. https://doi.org/10.1074/jbc.M901790200.CrossRefPubMedPubMedCentral

63.

Camps C, Saini HK, Mole DR, Choudhry H, Reczko M, Guerra-Assunção JA, et al. Integrated analysis of microRNA and mRNA expression and association with HIF binding reveals the complexity of microRNA expression regulation under hypoxia. Mol Cancer. 2014;13(1):28. https://doi.org/10.1186/1476-4598-13-28.CrossRefPubMedPubMedCentral

64.

Xia X, Lemieux ME, Li W, Carroll JS, Brown M, Liu XS, et al. Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc Natl Acad Sci. 2009;106(11):4260–5. https://doi.org/10.1073/pnas.0810067106.CrossRefPubMedPubMedCentral

65.

Huang Y, Lin D, Taniguchi CM. Hypoxia inducible factor (HIF) in the tumor microenvironment: Friend or foe? Sci China Life Sci. 2017;60(10):1114–24. https://doi.org/10.1007/s11427-017-9178-y.CrossRefPubMedPubMedCentral

66.

Melvin A, Rocha S. Chromatin as an oxygen sensor and active player in the hypoxia response. Cell Signal. 2012;24(1):35–43. https://doi.org/10.1016/j.cellsig.2011.08.019.CrossRefPubMedPubMedCentral

67.

Batie M, Frost J, Frost M, Wilson JW, Schofield P, Rocha S. Hypoxia induces rapid changes to histone methylation and reprograms chromatin. Science. 2019;363(6432):1222–6. https://doi.org/10.1126/science.aau5870.CrossRefPubMed

68.

Chakraborty AA, Laukka T, Myllykoski M, Ringel AE, Booker MA, Tolstorukov MY, et al. Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate. Science. 2019;363(6432):1217–22. https://doi.org/10.1126/science.aaw1026.CrossRefPubMedPubMedCentral

69.

Liu L, Cash TP, Jones RG, Keith B, Thompson CB, Simon MC. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol Cell. 2006;21(4):521–31. https://doi.org/10.1016/j.molcel.2006.01.010.CrossRefPubMedPubMedCentral

70.

Hetz C, Saxena S. ER stress and the unfolded protein response in neurodegeneration. Nat Rev Neurol. 2017;13(8):477–91. https://doi.org/10.1038/nrneurol.2017.99.CrossRefPubMed

71.

Kurokawa T, Miyamoto M, Kato K, Cho Y, Kawarada Y, Hida Y, et al. Overexpression of hypoxia-inducible-factor 1 α (HIF-1 α ) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Br J Cancer. 2003;89(6):1042–7. https://doi.org/10.1038/sj.bjc.6601186.CrossRefPubMedPubMedCentral

72.

Baba Y, Nosho K, Shima K, Irahara N, Chan AT, Meyerhardt JA, et al. HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol. 2010;176(5):2292–301. https://doi.org/10.2353/ajpath.2010.090972.CrossRefPubMedPubMedCentral

73.

Miyake K, Yoshizumi T, Imura S, Sugimoto K, Batmunkh E, Kanemura H, et al. Expression of hypoxia-inducible factor-1α, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: Correlation with poor prognosis with possible regulation. Pancreas. 2008;36(3):e1–9. https://doi.org/10.1097/MPA.0b013e31815f2c2a.CrossRefPubMed

74.

Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G. Expression of hypoxia-inducible factor 1α in epithelial ovarian tumors: Its impact on prognosis and on response to chemotherapy. Clin Cancer Res. 2001;7(6):1661–8.PubMed

75.

Yan M, Rayoo M, Takano EA, Thorne H, Fox SB. BRCA1 tumours correlate with a HIF-1 α phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression. Br J Cancer. 2009;101(7):1168–74. https://doi.org/10.1038/sj.bjc.6605287.CrossRefPubMedPubMedCentral

76.

Seeber LM, Horrée N, van der Groep P, van der Wall E, Verheijen RH, van Diest PJ. Necrosis related HIF-1α expression predicts prognosis in patients with endometrioid endometrial carcinoma. BMC Cancer. 2010;10(1):307. https://doi.org/10.1186/1471-2407-10-307.CrossRefPubMedPubMedCentral

77.

Batmunkh E, Shimada M, Morine Y, Imura S, Kanemura H, Arakawa Y, et al. Expression of hypoxia-inducible factor-1 alpha (HIF-1α) in patients with the gallbladder carcinoma. Int J Clin Oncol. 2010;15(1):59–64. https://doi.org/10.1007/s10147-009-0011-7.CrossRefPubMed

78.

Chen L, Shi Y, Yuan J, Han Y, Qin R, Wu Q, et al. HIF-1 alpha overexpression correlates with poor overall survival and disease-free survival in gastric cancer patients post-gastrectomy. PLoS One. 2014;9(3):e90678. https://doi.org/10.1371/journal.pone.0090678.CrossRefPubMedPubMedCentral

79.

Huang M, Chen Q, Xiao J, Yao T, Bian L, Liu C, et al. Overexpression of hypoxia-inducible factor-1α is a predictor of poor prognosis in cervical cancer: a clinicopathologic study and a meta-analysis. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2014;24(6):1054–64. https://doi.org/10.1097/IGC.0000000000000162.CrossRef

80.

Wang Q, Hu D, Rui Y, Jiang A, Liu Z, Huang L. Prognosis value of HIF-1α expression in patients with non-small cell lung cancer. Gene. 2014;541(2):69–74. https://doi.org/10.1016/j.gene.2014.03.025.CrossRefPubMed

81.

Zheng Y, Ni Y, Huang X, Wang Z, Han W. Overexpression of HIF-1α indicates a poor prognosis in tongue carcinoma and may be associated with tumour metastasis. Oncol Lett. 2013;5(4):1285–9. https://doi.org/10.3892/ol.2013.1185.CrossRefPubMedPubMedCentral

82.

Theodoropoulos VE, Lazaris AC, Sofras F, Gerzelis I, Tsoukala V, Ghikonti I, et al. Hypoxia-inducible factor 1α expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol. 2004;46(2):200–8. https://doi.org/10.1016/j.eururo.2004.04.008.CrossRefPubMed

83.

Klabatsa A, Sheaff MT, Steele JPC, Evans MT, Rudd RM, Fennell DA. Expression and prognostic significance of hypoxia-inducible factor 1α (HIF-1α) in malignant pleural mesothelioma (MPM). Lung Cancer. 2006;51(1):53–9. https://doi.org/10.1016/j.lungcan.2005.07.010.CrossRefPubMed

84.

Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, Richter E, et al. The hypoxia-inducible factor-1 α is a negative factor for tumor therapy. Oncogene. 2003;22(21):3213–20. https://doi.org/10.1038/sj.onc.1206385.CrossRefPubMed

85.

Gao Z-J, Wang Y, Yuan W, Yuan J, Yuan K. HIF-2α not HIF-1α overexpression confers poor prognosis in non–small cell lung cancer. Tumor Biol. 2017;39(6):1010428317709637. https://doi.org/10.1177/1010428317709637.CrossRef

86.

Han S, Huang T, Li W, Liu S, Yang W, Shi Q, et al. Association between hypoxia-inducible factor-2α (HIF-2α) expression and colorectal cancer and its prognostic role: a systematic analysis. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2018;48(2):516–27. https://doi.org/10.1159/000491806.CrossRef

87.

Scrideli CA, Carlotti CG, Mata JF, Neder L, Machado HR, Oba-Sinjo SM, et al. Prognostic significance of co-overexpression of the EGFR/IGFBP-2/HIF-2A genes in astrocytomas. J Neuro-Oncol. 2007;83(3):233–9. https://doi.org/10.1007/s11060-007-9328-0.CrossRef

88.

Bangoura G, Liu Z-S, Qian Q, Jiang C-Q, Yang G-F, Jing S. Prognostic significance of HIF-2α/EPAS1 expression in hepatocellular carcinoma. World J Gastroenterol WJG. 2007;13(23):3176–82. https://doi.org/10.3748/wjg.v13.i23.3176.CrossRefPubMed

89.

Lim E, Kuo C-C, Tu H-F, Yang C-C. The prognosis outcome of oral squamous cell carcinoma using HIF-2α. J Chin Med Assoc. 2017;80(10):651–6. https://doi.org/10.1016/j.jcma.2017.06.005.CrossRefPubMed

90.

Ioachim E, Michael M, Salmas M, Michael MM, Stavropoulos NE, Malamou-Mitsi V. Hypoxia-inducible factors HIF-1α and HIF-2α expression in bladder cancer and their associations with other angiogenesis-related proteins. Urol Int. 2006;77(3):255–63. https://doi.org/10.1159/000094819.CrossRefPubMed

91.

Martínez-Sáez O, Gajate Borau P, Alonso-Gordoa T, Molina-Cerrillo J, Grande E. Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy. Crit Rev Oncol Hematol. 2017;111:117–23. https://doi.org/10.1016/j.critrevonc.2017.01.013.CrossRefPubMed

92.

Jiang BH, Semenza GL, Bauer C, Marti HH. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol-Cell Physiol. 1996;271(4):C1172–80. https://doi.org/10.1152/ajpcell.1996.271.4.C1172.CrossRef

93.

Yu AY, Frid MG, Shimoda LA, Wiener CM, Stenmark K, Semenza GL. Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung. Am J Physiol Lung Cell Mol Physiol. 1998;275(4):L818–26. https://doi.org/10.1152/ajplung.1998.275.4.L818.CrossRef

94.

Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: Role of reoxygenation, free radicals, and stress granules. Cancer Cell. 2004;5(5):429–41. https://doi.org/10.1016/S1535-6108(04)00115-1.CrossRefPubMed

95.

Chandel NS, McClintock DS, Feliciano CE, Wood TM, Melendez JA, Rodriguez AM, et al. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1α during hypoxia. J Biol Chem. 2000;275(33):25130–8. https://doi.org/10.1074/jbc.M001914200.CrossRefPubMed

96.

Gerald D, Berra E, Frapart YM, Chan DA, Giaccia AJ, Mansuy D, et al. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell. 2004;118(6):781–94. https://doi.org/10.1016/j.cell.2004.08.025.CrossRefPubMed

97.

Bell E, Klimova T, Eisenbart J, Morase C, Murphy M, Budinger S, et al. The Qo site of the mitochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production. J Cell Biol. 2007;177(6):1029–936. https://doi.org/10.1083/jcb.200609074.CrossRefPubMedPubMedCentral

98.

Klimova T, Chandel NS. Mitochondrial complex III regulates hypoxic activation of HIF. Cell Death Differ. 2008;15(4):660–6. https://doi.org/10.1038/sj.cdd.4402307.CrossRefPubMed

99.

Sasabe E, Yang Z, Ohno S, Yamamoto T. Reactive oxygen species produced by the knockdown of manganese-superoxide dismutase up-regulate hypoxia-inducible factor-1alpha expression in oral squamous cell carcinoma cells. Free Radic Biol Med. 2010;48(10):1321–9. https://doi.org/10.1016/j.freeradbiomed.2010.02.013.CrossRefPubMed

100.

Movafagh S, Crook S, Vo K. Regulation of hypoxia-inducible factor-1a by reactive oxygen species : New developments in an old debate. J Cell Biochem. 2015;116(5):696–703. https://doi.org/10.1002/jcb.25074.CrossRefPubMed

101.

Waypa GB, Smith KA, Schumacker PT. O2 sensing, mitochondria and ROS signaling: The fog is lifting. Mol Asp Med. 2016;47–48:76–89. https://doi.org/10.1016/j.mam.2016.01.002.CrossRef

102.

Smith KA, Waypa GB, Schumacker PT. Redox signaling during hypoxia in mammalian cells. Redox Biol. 2017;13:228–34. https://doi.org/10.1016/j.redox.2017.05.020.CrossRefPubMedPubMedCentral

103.

Chen R, Lai UH, Zhu L, Singh A, Ahmed M, Forsyth NR. Reactive oxygen species formation in the brain at different oxygen levels: The role of hypoxia inducible factors. Front Cell Dev Biol. 2018;6 https://doi.org/10.3389/fcell.2018.00132.

104.

Kim W-Y, Oh SH, Woo J-K, Hong WK, Lee H-Y. Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha. Cancer Res. 2009;69(4):1624–32. https://doi.org/10.1158/0008-5472.CAN-08-0505.CrossRefPubMedPubMedCentral

105.

Katschinski DM, Le L, Heinrich D, Wagner KF, Hofer T, Schindler SG, et al. Heat induction of the unphosphorylated form of hypoxia-inducible factor-1alpha is dependent on heat shock protein-90 activity. J Biol Chem. 2002;277(11):9262–7. https://doi.org/10.1074/jbc.M110377200.CrossRefPubMed

106.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. https://doi.org/10.1016/j.cell.2011.02.013.CrossRefPubMed

107.

Asati V, Kar Mahapatra D, Kumar BS. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives. Eur J Med Chem. 2016;109:314–41. https://doi.org/10.1016/j.ejmech.2016.01.012.CrossRefPubMed

108.

Hein AL, Ouellette MM, Yan Y. Radiation-induced signaling pathways that promote cancer cell survival (Review). Int J Oncol. 2014;45(5):1813–9. https://doi.org/10.3892/ijo.2014.2614.CrossRefPubMedPubMedCentral

109.

Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers. 2017;9(5):52. https://doi.org/10.3390/cancers9050052.CrossRefPubMedCentral

110.

Munshi A, Ramesh R. Mitogen-activated protein kinases and their role in radiation response. Genes Cancer. 2013;4(9–10):401–8. https://doi.org/10.1177/1947601913485414.CrossRefPubMedPubMedCentral

111.

Harada H, Itasaka S, Kizaka-Kondoh S, Shibuya K, Morinibu A, Shinomiya K, et al. The Akt/mTOR pathway assures the synthesis of HIF-1α protein in a glucose- and reoxygenation-dependent manner in irradiated tumors. J Biol Chem. 2009;284(8):5332–42. https://doi.org/10.1074/jbc.M806653200.CrossRefPubMed

112.

Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase aignaling in colon cancer cells. J Biol Chem. 2002;277(41):38205–11. https://doi.org/10.1074/jbc.M203781200.CrossRefPubMed

113.

Barker HE, Paget JTE, Khan AA, Harrington KJ. The Tumour microenvironment after radiotherapy: Mechanisms of resistance and recurrence. Nat Rev Cancer. 2015;15(7):409–25. https://doi.org/10.1038/nrc3958.CrossRefPubMedPubMedCentral

114.

Barcellos-Hoff MH. Remodeling the irradiated tumor microenvironment: The fifth R of radiobiology? In: Tofilon PJ, Camphausen K, editors. Increasing the therapeutic ratio of radiotherapy. Cham: Springer International Publishing; 2017. p. 135–49. https://doi.org/10.1007/978-3-319-40854-5_6.CrossRef

115.

Jarosz-Biej M, Smolarczyk R, Cichoń T, Kułach N. Tumor microenvironment as a “game changer” in cancer radiotherapy. Int J Mol Sci. 2019;20(13):3212. https://doi.org/10.3390/ijms20133212.CrossRefPubMedCentral

116.

Herrera FG, Bourhis J, Coukos G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice. CA Cancer J Clin. 2017;67(1):65–85. https://doi.org/10.3322/caac.21358.CrossRefPubMed

117.

Wennerberg E, Lhuillier C, Vanpouille-Box C, Pilones KA, García-Martínez E, Rudqvist N-P, et al. Barriers to radiation-induced in situ tumor vaccination. Front Immunol. 2017;8:229. https://doi.org/10.3389/fimmu.2017.00229.CrossRefPubMedPubMedCentral

118.

Grassberger C, Ellsworth SG, Wilks MQ, Keane FK, Loeffler JS. Assessing the interactions between radiotherapy and antitumour immunity. Nat Rev Clin Oncol. 2019;16(12):729–45. https://doi.org/10.1038/s41571-019-0238-9.CrossRefPubMed

119.

Deutsch E, Chargari C, Galluzzi L, Kroemer G. Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy. Lancet Oncol. 2019;20(8):e452–63. https://doi.org/10.1016/S1470-2045(19)30171-8.CrossRefPubMed

120.

Pitroda SP, Chmura SJ, Weichselbaum RR. Integration of radiotherapy and immunotherapy for treatment of oligometastases. Lancet Oncol. 2019;20(8):e434–42. https://doi.org/10.1016/S1470-2045(19)30157-3.CrossRefPubMed

121.

Li Y, Patel SP, Roszik J, Qin Y. Hypoxia-driven immunosuppressive metabolites in the tumor microenvironment: New approaches for combinational immunotherapy. Front Immunol. 2018;9:1591. https://doi.org/10.3389/fimmu.2018.01591.CrossRefPubMedPubMedCentral

122.

Wang B, Zhao Q, Zhang Y, Liu Z, Zheng Z, Liu S, et al. Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy. J Exp Clin Cancer Res. 2021;40(1):24. https://doi.org/10.1186/s13046-020-01820-7.CrossRefPubMedPubMedCentral

123.

Park HJ, Griffin RJ, Hui S, Levitt SH, Song CW. Radiation-induced vascular damage in tumors: Implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res. 2012;177(3):311–27. https://doi.org/10.1667/RR2773.1.CrossRefPubMed

124.

Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005;69(3):4–10. https://doi.org/10.1159/000088478.CrossRefPubMed

125.

Hellweg CE. The Nuclear Factor κB pathway: A link to the immune system in the radiation response. Cancer Lett. 2015;368(2):275–89. https://doi.org/10.1016/j.canlet.2015.02.019.CrossRefPubMed

126.

Baselet B, Sonveaux P, Baatout S, Aerts A. Pathological effects of ionizing radiation: endothelial activation and dysfunction. Cell Mol Life Sci. 2019;76(4):699–728. https://doi.org/10.1007/s00018-018-2956-z.CrossRefPubMed

127.

Gandhi S, Chandna S. Radiation-induced inflammatory cascade and its reverberating crosstalks as potential cause of post-radiotherapy second malignancies. Cancer Metastasis Rev. 2017;36(2):375–93. https://doi.org/10.1007/s10555-017-9669-x.CrossRefPubMed

128.

Yarnold J, Vozenin Brotons M-C. Pathogenetic mechanisms in radiation fibrosis. Radiother Oncol. 2010;97(1):149–61. https://doi.org/10.1016/j.radonc.2010.09.002.CrossRefPubMed

129.

Distler JHW, Jüngel A, Pileckyte M, Zwerina J, Michel BA, Gay RE, et al. Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum. 2007;56(12):4203–15. https://doi.org/10.1002/art.23074.CrossRefPubMed

130.

Darby I, Hewitson T. Hypoxia in tissue repair and fibrosis. Cell Tissue Res. 2016;365(3):553–62. https://doi.org/10.1007/s00441-016-2461-3.CrossRefPubMed

131.

Barbazán J, Matic VD. Cancer associated fibroblasts: is the force the path to the dark side? Curr Opin Cell Biol. 2019;56:71–9. https://doi.org/10.1016/j.ceb.2018.09.002.CrossRefPubMed

132.

Wang Z, Tang Y, Tan Y, Wei Q, Yu W. Cancer-associated fibroblastas in radiotherapy: challenges and new opportunities. Cell Commun Signal. 2019;17(1):47. https://doi.org/10.1186/s12964-019-0362-2.CrossRefPubMedPubMedCentral

133.

Tam SY, Wu VWC, Law HKW. Hypoxia-induced epithelial-mesenchymal transition in cancers: HIF-1α and beyond. Front Oncol. 2020;10:486. https://doi.org/10.3389/fonc.2020.00486.CrossRefPubMedPubMedCentral

134.

Tommelein J, De Vlieghere E, Verset L, Melsens E, Leenders J, Descamps B, et al. Radiotherapy-activated cancer-associated fibroblasts promote tumor progression through paracrine IGF1R activation. Cancer Res. 2018;78(3):659–70. https://doi.org/10.1158/0008-5472.CAN-17-0524.CrossRefPubMed

135.

Zhang H, Yue J, Jiang Z, Zhou R, Xie R, Xu Y, et al. CAF-secreted CXCL1 conferred radioresistance by regulating DNA damage response in a ROS-dependent manner in esophageal squamous cell carcinoma. Cell Death Dis. 2017;8(5):e2790. https://doi.org/10.1038/cddis.2017.180.CrossRefPubMedPubMedCentral

136.

DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2(5):e1600200. https://doi.org/10.1126/sciadv.1600200.CrossRefPubMedPubMedCentral

137.

Heiden MGV, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–33. https://doi.org/10.1126/science.1160809.CrossRef

138.

Frezza C. Metabolism and cancer: the future is now. Br J Cancer. 2020;122(2):133–5. https://doi.org/10.1038/s41416-019-0667-3.CrossRefPubMed

139.

Ebert BL, Firth JD, Ratcliffe PJ. Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct cis-acting sequences (*). J Biol Chem. 1995;270(49):29083–9. https://doi.org/10.1074/jbc.270.49.29083.CrossRefPubMed

140.

Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, Zeller KI, et al. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell. 2007;11(5):407–20. https://doi.org/10.1016/j.ccr.2007.04.001.CrossRefPubMed

141.

Semenza GL. Mitochondrial autophagy: Life and breath of the cell. Autophagy. 2008;4(4):534–6. https://doi.org/10.4161/auto.5956.CrossRefPubMed

142.

Goodwin ML, Gladden BL, Nijsten MWN, Jones KB. Lactate and cancer: revisiting the Warburg effect in an era of lactate shuttling. Front Nutr. 2015;1:27. doi. https://doi.org/10.3389/fnut.2014.00027.CrossRefPubMedPubMedCentral

143.

Nagao A, Kobayashi M, Koyasu S, Chow CCT, Harada H. HIF-1-dependent reprogramming of glucose metabolic pathway of cancer cells and its therapeutic significance. Int J Mol Sci. 2019;20(2):238. https://doi.org/10.3390/ijms20020238.CrossRefPubMedCentral

144.

Meijer TWH, Kaanders JHAM, Span PN, Bussink J. Targeting hypoxia, HIF-1, and tumor glucose metabolism to Improve radiotherapy efficacy. Clin Cancer Res. 2012;18(20):5585–94. https://doi.org/10.1158/1078-0432.CCR-12-0858.CrossRefPubMed

145.

Courtnay R, Ngo DC, Malik N, Ververis K, Tortorella SM, Karagiannis TC. Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K. Mol Biol Rep. 2015;42(4):841–51. https://doi.org/10.1007/s11033-015-3858-x.CrossRefPubMed

146.

DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW. Hypoxia regulates TSC1/2–mTOR signaling and tumor suppression through REDD1-mediated 14–3–3 shuttling. Genes Dev. 2008;22(2):239–51. https://doi.org/10.1101/gad.1617608.CrossRefPubMedPubMedCentral

147.

Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004;18(23):2893–904. https://doi.org/10.1101/gad.1256804.CrossRefPubMedPubMedCentral

148.

Chen D, Li M, Luo J, Gu W. Direct Interactions between HIF-1α and Mdm2 Modulate p53 Function*. J Biol Chem. 2003;278(16):13595–8. https://doi.org/10.1074/jbc.C200694200.CrossRefPubMed

149.

Moeller BJ, Dreher MR, Rabbani ZN, Schroeder T, Cao Y, Li CY, et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell. 2005;8(2):99–110. https://doi.org/10.1016/j.ccr.2005.06.016.CrossRefPubMed

150.

Moeller BJ, Dewhirst MW. HIF-1 and tumour radiosensitivity. Br J Cancer. 2006;95(1):1–5. https://doi.org/10.1038/sj.bjc.6603201.CrossRefPubMedPubMedCentral

151.

Rohwer N, Cramer T. Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat. 2011;14(3):191–201. https://doi.org/10.1016/j.drup.2011.03.001.CrossRefPubMed

152.

Huang R, Zhou P-K. HIF-1 signaling: A key orchestrator of cancer radioresistance. Radiat Med Prot. 2020;1(1):7–14. https://doi.org/10.1016/j.radmp.2020.01.006.CrossRef

153.

Tang L, Wei F, Wu Y, He Y, Shi L, Xiong F, et al. Role of metabolism in cancer cell radioresistance and radiosensitization methods. J Exp Clin Cancer Res CR. 2018;37(1):87. https://doi.org/10.1186/s13046-018-0758-7.CrossRefPubMed

154.

Madan E, Gogna R, Bhatt M, Pati U, Kuppusamy P, Mahdi AA. Regulation of glucose metabolism by p53: emerging new roles for the tumor suppressor. Oncotarget. 2011;2(12):948–57. https://doi.org/10.18632/oncotarget.389.CrossRefPubMedPubMedCentral

155.

Green DR, Chipuk JE. p53 and Metabolism: Inside the TIGAR. Cell. 2006;126(1):30–2. https://doi.org/10.1016/j.cell.2006.06.032.CrossRefPubMed

156.

Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989;49(23):6449–65.PubMed

157.

Vaupel P, Schlenger K, Knoop C, Höckel M. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res. 1991;51(12):3316–22.PubMed

158.

Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol. 2012;9(12):674–87. https://doi.org/10.1038/nrclinonc.2012.171.CrossRefPubMed

159.

Stieb S, Eleftheriou A, Warnock G, Guckenberger M, Riesterer O. Longitudinal PET imaging of tumor hypoxia during the course of radiotherapy. Eur J Nucl Med Mol Imaging. 2018;45(12):2201–17. https://doi.org/10.1007/s00259-018-4116-y.CrossRefPubMed

160.

Rickard AG, Palmer GM, Dewhirst MW. Clinical and pre-clinical methods for quantifying tumor hypoxia. In: Gilkes DM, editor. Hypoxia cancer metastasis. Cham: Springer International Publishing; 2019. p. 19–41. https://doi.org/10.1007/978-3-030-12734-3_2.CrossRef

161.

Bussink J, Kaanders JHAM, van der Kogel AJ. Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol. 2003;67(1):3–15. https://doi.org/10.1016/S0167-8140(03)00011-2.CrossRefPubMed

162.

Mayer A, Höckel M, Vaupel P. Endogenous hypoxia markers: Case not proven! In: Kang KA, Harrison DK, Bruley DF, editors. Oxygen transport to tissue XXIX, vol. 614. Boston, MA: Springer; 2008.CrossRef

163.

Harris BHL, Barberis A, West CML, Buffa FM. Gene expression signatures as biomarkers of tumour xypoxia. Clin Oncol. 2015;27(10):547–60. https://doi.org/10.1016/j.clon.2015.07.004.CrossRef

164.

Brown JM. Clinical trials of radiosensitizers: What should we expect? Int J Radiat Oncol. 1984;10(3):425–9. https://doi.org/10.1016/0360-3016(84)90063-4.CrossRef

165.

Höckel M, Vorndran B, Schlenger K, Baußmann E, Knapstein PG. Tumor oxygenation: A new predictive parameter in locally advanced cancer of the uterine cervix. Gynecol Oncol. 1993;51(2):141–9. https://doi.org/10.1006/gyno.1993.1262.CrossRefPubMed

166.

Fyles AW, Milosevic M, Wong R, Kavanagh M-C, Pintilie M, Sun A, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol. 1998;48(2):149–56. https://doi.org/10.1016/S0167-8140(98)00044-9.CrossRefPubMed

167.

Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 1996;41(1):31–9. https://doi.org/10.1016/S0167-8140(96)91811-3.CrossRefPubMed

168.

Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol. 2007;25(26):4066–74. https://doi.org/10.1200/JCO.2007.12.7878.CrossRefPubMed

169.

Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck--a systematic review and meta-analysis. Radiother Oncol. 2011;100(1):22–32. https://doi.org/10.1016/j.radonc.2011.03.004.CrossRefPubMed

170.

Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004;4(6):437–47. https://doi.org/10.1038/nrc1367.CrossRefPubMed

171.

Withers HR, Lett JT, Adler H. The four R’s of radiotherapy. Adv Radiat Biol. 1975;5:241–71. https://doi.org/10.1016/B978-0-12-035405-4.50012-8.CrossRef

172.

Potters L, Kavanagh B, Galvin JM, Hevezi JM, Janjan NA, Larson DA, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2010;76:326–32. https://doi.org/10.1016/j.ijrobp.2009.09.042.CrossRefPubMed

173.

Lo SS, Fakiris AJ, Chang EL, Mayr NA, Wang JZ, Papiez L, et al. Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol. 2010;7(1):44–54. https://doi.org/10.1038/nrclinonc.2009.188.CrossRefPubMed

174.

Brown JM, Carlson DJ, Brenner DJ. The tumor radiobiology of SRS and SBRT: Are more than the 5 R’s involved? Int J Radiat Oncol Biol Phys. 2014;88(2):254–62. https://doi.org/10.1016/j.ijrobp.2013.07.022.CrossRefPubMedPubMedCentral

175.

Song CW, Glatstein E, Marks LB, Emami B, Grimm J, Sperduto PW, et al. Biological principles of stereotactic body radiation therapy (SBRT) and stereotactic radiation surgery (SRS): Indirect cell death. Int J Radiat Oncol. 2019;110(1):21–34. https://doi.org/10.1016/j.ijrobp.2019.02.047.CrossRef

176.

Carlson DJ, Keall PJ, Loo BW, Chen ZJ, Brown JM. Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia. Int J Radiat Oncol. 2011;79(4):1188–95. https://doi.org/10.1016/j.ijrobp.2010.10.007.CrossRef

177.

Adams GE, Cooke MS. Electron-affinic sensitization. Int J Radiat Biol Relat Stud Phys Chem Med. 1969;15(5):457–71. https://doi.org/10.1080/09553006914550741.CrossRefPubMed

178.

Denekamp J, Fowler JF, McNally NJ. Hypoxic cell sensitizers: early or late in fractionated therapy? Br J Cancer. 1978;37(5):858–60. https://doi.org/10.1038/bjc.1978.125.CrossRefPubMedPubMedCentral

179.

Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res. 1994;6(10-11):509–18.PubMed

180.

Das DS, Tian Z, Ray A, Ravillah D, Song Y, Richardson PG, et al. Anti-myeloma activity of a novel free radical inducer Rrx-001. Blood. 2014;124(21):4712. https://doi.org/10.1182/blood.V124.21.4712.4712.CrossRef

181.

Oronsky B, Scicinski J, Ning S, Peehl D, Oronsky A, Cabrales P, et al. RRx-001, A novel dinitroazetidine radiosensitizer. Investig New Drugs. 2016;34(3):371–7. https://doi.org/10.1007/s10637-016-0326-y.CrossRef

182.

Kim MM, Parmar HA, Schipper M, Devasia T, Aryal MP, Kesari S, et al. BRAINSTORM: A multi-institutional phase 1/2 Study of RRx-001 in combination with whole brain radiation therapy for patients with brain metastases. Int J Radiat Oncol. 2020;107(3):478–86. https://doi.org/10.1016/j.ijrobp.2020.02.639.CrossRef

183.

Toustrup K, Sørensen BS, Nordsmark M, Busk M, Wiuf C, Alsner J, et al. Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res. 2011;71(17):5923–31. https://doi.org/10.1158/0008-5472.CAN-11-1182.CrossRefPubMed

184.

Overgaard J, Sand Hansen H, Overgaard M, Bastholt L, Berthelsen A, Specht L, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol. 1998;46(2):135–46. https://doi.org/10.1016/S0167-8140(97)00220-X.CrossRefPubMed

185.

Toustrup K, Sørensen BS, Alsner J, Overgaard J. Hypoxia gene expression signatures as prognostic and predictive markers in head and neck radiotherapy. Semin Radiat Oncol. 2012;22(2):119–27. https://doi.org/10.1016/j.semradonc.2011.12.006.CrossRefPubMed

186.

Toustrup K, Sørensen BS, Lassen P, Wiuf C, Alsner J, Overgaard J. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol. 2012;102(1):122–9. https://doi.org/10.1016/j.radonc.2011.09.010.CrossRefPubMed

187.

Hassan Metwally MA, Ali R, Kuddu M, Shouman T, Strojan P, Iqbal K, et al. IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma. Radiother Oncol. 2015;116(1):15–20. https://doi.org/10.1016/j.radonc.2015.04.005.CrossRefPubMed

188.

Mohindra JK, Rauth AM. Increased cell killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells. Cancer Res. 1976;36(3):930–6.PubMed

189.

Ahn G-O, Brown M. Targeting tumors with hypoxia-activated cytotoxins. Front Biosci J Virtual Libr. 2007;12(8-12):3483–501. https://doi.org/10.2741/2329.CrossRef

190.

Mistry IN, Thomas M, Calder EDD, Conway SJ, Hammond EM. Clinical advances of hypoxia-activated prodrugs in combination with radiation therapy. Int J Radiat Oncol. 2017;98(5):1183–96. https://doi.org/10.1016/j.ijrobp.2017.03.024.CrossRef

191.

Le Q-T, Taira A, Budenz S, Dorie MJ, Goffinet DR, Fee WE, et al. Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable stage IV head and neck squamous cell carcinomas. Cancer. 2006;106(9):1940–9. https://doi.org/10.1002/cncr.21785.CrossRefPubMed

192.

Peters LJ, O’Sullivan B, Giralt J, Fitzgerald TJ, Trotti A, Bernier J, et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol. 2010;28(18):2996–3001. https://doi.org/10.1200/JCO.2009.27.4498.CrossRefPubMed

193.

Hay M, Hicks K, Wilson W. Discovery of the hypoxia-activated prodrug SN30000. In: Comprehensive medicinal chemistry III. 3rd ed. Amsterdam: Elsevier; 2017. p. 58–94.CrossRef

194.

Mao X, McManaway S, Jaiswal JK, Hong CR, Wilson WR, Hicks KO. Schedule-dependent potentiation of chemotherapy drugs by the hypoxia-activated prodrug SN30000. Cancer Biol Ther. 2019;20(9):1258–69. https://doi.org/10.1080/15384047.2019.1617570.CrossRefPubMedPubMedCentral

195.

Liu Q, Sun JD, Wang J, Ahluwalia D, Baker AF, Cranmer LD, et al. TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. Cancer Chemother Pharmacol. 2012;69(6):1487–98. https://doi.org/10.1007/s00280-012-1852-8.CrossRefPubMedPubMedCentral

196.

McKeage MJ, Jameson MB, Ramanathan RK, Rajendran J, Gu Y, Wilson WR, et al. PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours. BMC Cancer. 2012;12(1):496. https://doi.org/10.1186/1471-2407-12-496.CrossRefPubMedPubMedCentral

197.

Sun JD, Liu Q, Wang J, Ahluwalia D, Ferraro D, Wang Y, et al. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clin Cancer Res. 2012;18(3):758–70. https://doi.org/10.1158/1078-0432.CCR-11-1980.CrossRefPubMed

198.

Meng F, Evans JW, Bhupathi D, Banica M, Lan L, Lorente G, et al. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Mol Cancer Ther. 2012;11(3):740–51. https://doi.org/10.1158/1535-7163.MCT-11-0634.CrossRefPubMed

199.

Hong CR, Dickson BD, Jaiswal JK, Pruijn FB, Hunter FW, Hay MP, et al. Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects. Biochem Pharmacol. 2018;156:265–80. https://doi.org/10.1016/j.bcp.2018.08.027.CrossRefPubMed

200.

Hong CR, Wilson WR, Hicks KO. An intratumor pharmacokinetic/pharmacodynamic model for the hypoxia-activated prodrug evofosfamide (TH-302): Monotherapy activity is not dependent on a bystander effect. Neoplasia. 2019;21(2):159–71. https://doi.org/10.1016/j.neo.2018.11.009.CrossRefPubMed

201.

Chawla SP, Cranmer LD, Van Tine BA, Reed DR, Okuno SH, Butrynski JE, et al. Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. J Clin Oncol. 2014;32(29):3299–306. https://doi.org/10.1200/JCO.2013.54.3660.CrossRefPubMedPubMedCentral

202.

Borad MJ, Reddy SG, Bahary N, Uronis HE, Sigal D, Cohn AL, et al. Randomized phase II trial of gemcitabine plus TH-302 versus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2015;33(13):1475–81. https://doi.org/10.1200/JCO.2014.55.7504.CrossRefPubMed

203.

Nytko KJ, Grgic I, Bender S, Ott J, Guckenberger M, Riesterer O, et al. The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy. Oncotarget. 2017;8(14):23702–12. https://doi.org/10.18632/oncotarget.15784.CrossRefPubMedPubMedCentral

204.

Peeters SGJA, Zegers CML, Biemans R, Lieuwes NG, van Stiphout RGPM, Yaromina A, et al. TH-302 in combination with radiotherapy enhances the therapeutic outcome and is associated with pretreatment [18F]HX4 hypoxia PET imaging. Clin Cancer Res. 2015;21(13):2984–92. https://doi.org/10.1158/1078-0432.CCR-15-0018.CrossRefPubMed

205.

Hajj C, Russell J, Hart CP, Goodman KA, Lowery MA, Haimovitz-Friedman A, et al. A combination of radiation and the hypoxia-activated prodrug evofosfamide (TH-302) is efficacious against a human orthotopic pancreatic tumor model. Transl Oncol. 2017;10(5):760–5. https://doi.org/10.1016/j.tranon.2017.06.010.CrossRefPubMedPubMedCentral

206.

Jameson MB, Rischin D, Pegram M, Gutheil J, Patterson AV, Denny WA, et al. A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemother Pharmacol. 2010;65(4):791–801. https://doi.org/10.1007/s00280-009-1188-1.CrossRefPubMed

207.

Konopleva M, Thall PF, Yi CA, Borthakur G, Coveler A, Bueso-Ramos C, et al. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica. 2015;100(7):927–34. https://doi.org/10.3324/haematol.2014.118455.CrossRefPubMedPubMedCentral

208.

Abou-Alfa GK, Chan SL, Lin C-C, Chiorean EG, Holcombe RF, Mulcahy MF, et al. PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2011;68(2):539–45. https://doi.org/10.1007/s00280-011-1671-3.CrossRefPubMed

209.

McKeage MJ, Gu Y, Wilson WR, Hill A, Amies K, Melink TJ, et al. A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients. BMC Cancer. 2011;11(1):432. https://doi.org/10.1186/1471-2407-11-432.CrossRefPubMedPubMedCentral

210.

Thiolloy S, Deschoemaeker S, Ongenae N, Gilissen J, Dubois L, Yaromina A, et al. Abstract 4959: CP-506, a next generation hypoxia-activated prodrug, as promising novel anti-cancer therapeutic. Cancer Res. 2018;78:4959. https://doi.org/10.1158/1538-7445.AM2018-4959.CrossRef

211.

Jayaprakash P, Ai M, Liu A, Budhani P, Bartkowiak T, Sheng J, et al. Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy. J Clin Invest. 2018;128(11):5137–49. https://doi.org/10.1172/JCI96268.CrossRefPubMedPubMedCentral

212.

Patterson AV, Jaiswal J, Carlin K, Abbattista MR, Guise CP, Silva S, et al. Abstract B278: PR610: A novel hypoxia-selective tyrosine kinase inhibitor in phase I clinical trial. Mol Cancer Ther. 2013;12:B278. https://doi.org/10.1158/1535-7163.TARG-13-B278.CrossRef

213.

Liu SV, Aggarwal C, Brzezniak C, Doebele RC, Gerber DE, Gitlitz B, et al. Phase 2 study of tarloxotinib bromide (TRLX) in patients (pts) with EGFR-Mutant, T790M-Negative NSCLC progressing on an EGFR TKI. J Clin Oncol. 2016;34(15_suppl):TPS9100. https://doi.org/10.1200/JCO.2016.34.15_suppl.TPS9100.CrossRef

214.

Rischin D, Boyer MJ, Brzezniak CE, Colevas AD, Doebele RC, Gilbert J, et al. A phase 2 study of tarloxotinib bromide (TRLX) in patients (Pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS). J Clin Oncol. 2016;34(15_suppl):TPS6105. https://doi.org/10.1200/JCO.2016.34.15_suppl.TPS6105.CrossRef

215.

Hua H, Kong Q, Zhang H, Wang J, Luo T, Jiang Y. Targeting mTOR for cancer therapy. J Hematol Oncol. 2019;12(1):71. https://doi.org/10.1186/s13045-019-0754-1.CrossRefPubMedPubMedCentral

216.

Drosten M, Barbacid M. Targeting the MAPK pathway in KRAS-driven tumors. Cancer Cell. 2020;37(4):543–50. https://doi.org/10.1016/j.ccell.2020.03.013.CrossRefPubMed

217.

Greenberger LM, Horak ID, Filpula D, Sapra P, Westergaard M, Frydenlund HF, et al. A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther. 2008;7(11):3598–608. https://doi.org/10.1158/1535-7163.MCT-08-0510.CrossRefPubMed

218.

Jeong W, Rapisarda A, Park SR, Kinders RJ, Chen A, Melillo G, et al. Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors. Cancer Chemother Pharmacol. 2014;2(2):343–8. https://doi.org/10.1007/s00280-013-2362-z.CrossRef

219.

Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G, Powis G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α. Mol Cancer Ther. 2004;3(3):233–44.PubMed

220.

Koh MY, Spivak-Kroizman T, Venturini S, Welsh S, Williams RR, Kirkpatrick DL, et al. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1α. Mol Cancer Ther. 2008;7(1):90–100. https://doi.org/10.1158/1535-7163.MCT-07-0463.CrossRefPubMed

221.

Palayoor ST, Mitchell JB, Cerna D, DeGraff W, John-Aryankalayil M, Coleman CN. PX-478, an inhibitor of hypoxia-inducible factor-1α, enhances radiosensitivity of prostate carcinoma cells. Int J Cancer. 2008;123(10):2430–7. https://doi.org/10.1002/ijc.23807.CrossRefPubMedPubMedCentral

222.

Zhao T, Ren H, Jia L, Chen J, Xin W, Yan F, et al. Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma. Oncotarget. 2014;6(4):2250–62. https://doi.org/10.18632/oncotarget.2948.CrossRefPubMedCentral

223.

Tibes R, Falchook GS, Von Hoff DD, Weiss GJ, Iyengar T, Kurzrock R, et al. Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1α. J Clin Oncol. 2010;28(15_suppl):3076. https://doi.org/10.1200/jco.2010.28.15_suppl.3076.CrossRef

224.

Rapisarda A, Uranchimeg B, Scudiero DA, Selby M, Sausville EA, Shoemaker RH, et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 2002;62(15):4316–24.PubMed

225.

Kummar S, Raffeld M, Juwara L, Horneffer Y, Strassberger A, Allen D, et al. Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors. Clin Cancer Res. 2011;17(15):5123–31. https://doi.org/10.1158/1078-0432.CCR-11-0682.CrossRefPubMedPubMedCentral

226.

Befani CD, Vlachostergios PJ, Hatzidaki E, Patrikidou A, Bonanou S, Simos G, et al. Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. J Mol Med. 2012;90(1):45–54. https://doi.org/10.1007/s00109-011-0805-8.CrossRefPubMed

227.

Zhu K, Chan W, Heymach J, Wilkinson M, McConkey DJ. Control of HIF-1α expression by eIF2α phosphorylation–mediated translational repression. Cancer Res. 2009;69(5):1836–43. https://doi.org/10.1158/0008-5472.CAN-08-4103.CrossRefPubMedPubMedCentral

228.

Kaluz S, Kaluzová M, Stanbridge EJ. Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1α C-terminal activation domain. Mol Cell Biol. 2006;26(15):5895–907. https://doi.org/10.1128/MCB.00552-06.CrossRefPubMedPubMedCentral

229.

Shin DH, Chun Y-S, Lee DS, Huang LE, Park J-W. Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood. 2008;111(6):3131–6. https://doi.org/10.1182/blood-2007-11-120576.CrossRefPubMed

230.

Cui H, Qin Q, Yang M, Zhang H, Liu Z, Yang Y, et al. Bortezomib enhances the radiosensitivity of hypoxic cervical cancer cells by inhibiting HIF-1α expression. Int J Clin Exp Pathol. 2015;8(8):9032–41.PubMedPubMedCentral

231.

Wang D, Qin Q, Jiang Q-J, Wang D-F. Bortezomib sensitizes esophageal squamous cancer cells to radiotherapy by suppressing the expression of HIF-1α and apoptosis proteins. J X-Ray Sci Technol. 2016;24(4):639–46. https://doi.org/10.3233/XST-160571.CrossRef

232.

Goktas S, Baran Y, Ural AU, Yazici S, Aydur E, Basal S, et al. Proteasome inhibitor bortezomib increases radiation sensitivity in androgen independent human prostate cancer cells. Urology. 2010;75(4):793–8. https://doi.org/10.1016/j.urology.2009.07.1215.CrossRefPubMed

233.

Chiu H-W, Lin S-W, Lin L-C, Hsu Y-H, Lin Y-F, Ho S-Y, et al. Synergistic antitumor effects of radiation and proteasome inhibitor treatment in pancreatic cancer through the induction of autophagy and the downregulation of TRAF6. Cancer Lett. 2015;365(2):229–39. https://doi.org/10.1016/j.canlet.2015.05.025.CrossRefPubMed

234.

Wu Y-H, Wu W-S, Lin L-C, Liu C-S, Ho S-Y, Wang B-J, et al. Bortezomib enhances radiosensitivity in oral cancer through inducing autophagy-mediated TRAF6 oncoprotein degradation. J Exp Clin Cancer Res CR. 2018;37(1):91. https://doi.org/10.1186/s13046-018-0760-0.CrossRefPubMed

235.

Forster C, Schilling D, Wank M, Schmid TE, Combs SE. EP-2323: Effects of the proteasome inhibitor bortezomib on radiosensitivity of glioblastoma cells. Radiother Oncol. 2018;127:S1281–2. https://doi.org/10.1016/S0167-8140(18)32632-X.CrossRef

236.

Hutt DM, Roth DM, Vignaud H, Cullin C, Bouchecareilh M. The histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition. PLoS One. 2014;9(8):e106224. https://doi.org/10.1371/journal.pone.0106224.CrossRefPubMedPubMedCentral

237.

Zhang C, Yang C, Feldman MJ, Wang H, Pang Y, Maggio DM, et al. Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha. Oncotarget. 2017;8(34):56110–25. https://doi.org/10.18632/oncotarget.18125.CrossRefPubMedPubMedCentral

238.

Baschnagel A, Russo A, Burgan WE, Carter D, Beam K, Palmieri D, et al. Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Mol Cancer Ther. 2009;8(6):1589–95. https://doi.org/10.1158/1535-7163.MCT-09-0038.CrossRefPubMedPubMedCentral

239.

Munshi A, Tanaka T, Hobbs ML, Tucker SL, Richon VM, Meyn RE. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of γ-H2AX foci. Mol Cancer Ther. 2006;5(8):1967–74. https://doi.org/10.1158/1535-7163.MCT-06-0022.CrossRefPubMed

240.

Diss E, Nalabothula N, Nguyen D, Chang E, Kwok Y, Carrier F. Vorinostat promotes hyper-radiosensitivity in wild type p53 human glioblastoma cells. J Clin Oncol Res. 2014;2:1–9.

241.

Saelen MG, Ree AH, Kristian A, Fleten KG, Furre T, Hektoen HH, et al. Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma. Radiat Oncol. 2012;7(1):165. https://doi.org/10.1186/1748-717X-7-165.CrossRefPubMedPubMedCentral

242.

Jonsson M, Ragnum HB, Julin CH, Yeramian A, Clancy T, Frikstad K-AM, et al. Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition. Br J Cancer. 2016;115(8):929–39. https://doi.org/10.1038/bjc.2016.278.CrossRefPubMedPubMedCentral

243.

Jhaveri K, Modi S. Ganetespib: research and clinical development. OncoTargets Ther. 2015;8:1849–58. https://doi.org/10.2147/OTT.S65804.CrossRef

244.

Isaacs JS, Jung Y-J, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem. 2002;277(33):29936–44. https://doi.org/10.1074/jbc.M204733200.CrossRefPubMed

245.

Mabjeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, Simons JW, et al. Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteosome pathway in prostate cancer cells. Cancer Res. 2002;62(9):2478–82.PubMed

246.

Hollingshead M, Alley M, Burger AM, Borgel S, Pacula-Cox C, Fiebig H-H, et al. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol. 2005;56(2):115–25. https://doi.org/10.1007/s00280-004-0939-2.CrossRefPubMed

247.

Park Y-S, Shin W-S, Kim C-S, Ahn CM, Qi X-F, Kim S-K. Molecular and cellular toxicological profiling of DNA bis-intercalator, quinoxaline compounds: echinomycin as the versatile lead. Mol Cell Toxicol. 2018;14(1):9–18. https://doi.org/10.1007/s13273-018-0002-8.CrossRef

248.

Kong D, Park EJ, Stephen AG, Calvani M, Cardellina JH, Monks A, et al. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res. 2005;65(19):9047–55. https://doi.org/10.1158/0008-5472.CAN-05-1235.CrossRefPubMed

249.

Wang Y, Liu Y, Bailey C, Zhang H, He M, Sun D, et al. Therapeutic targeting of TP53 -mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin. Oncogene. 2020;39(14):3015–27. https://doi.org/10.1038/s41388-020-1201-z.CrossRefPubMedPubMedCentral

250.

Baker AF, Dragovich T, Tate WR, Ramanathan RK, Roe D, Hsu C-H, et al. The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma. J Lab Clin Med. 2006;147(2):83–90. https://doi.org/10.1016/j.lab.2005.09.001.CrossRefPubMedPubMedCentral

251.

Kim YH, Coon A, Baker AF, Powis G. Antitumor agent PX-12 inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferase. Cancer Chemother Pharmacol. 2011;68(2):405–13. https://doi.org/10.1007/s00280-010-1500-0.CrossRefPubMed

252.

You BR, Shin HR, Park WH. PX-12 inhibits the growth of A549 lung cancer cells via G2/M phase arrest and ROS-dependent apoptosis. Int J Oncol. 2014;44(1):301–8. https://doi.org/10.3892/ijo.2013.2152.CrossRefPubMed

253.

You BR, Shin HR, Han BR, Park WH. PX-12 induces apoptosis in Calu-6 cells in an oxidative stress-dependent manner. Tumor Biol. 2015;36(3):2087–95. https://doi.org/10.1007/s13277-014-2816-x.CrossRef

254.

Ramanathan RK, Abbruzzese J, Dragovich T, Kirkpatrick L, Guillen JM, Baker AF, et al. A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. Cancer Chemother Pharmacol. 2011;67(3):503–9. https://doi.org/10.1007/s00280-010-1343-8.CrossRefPubMed

255.

Kung AL, Zabludoff SD, France DS, Freedman SJ, Tanner EA, Vieira A, et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell. 2004;6(1):33–43. https://doi.org/10.1016/j.ccr.2004.06.009.CrossRefPubMed

256.

Jin Z, Aixi Y, Baiwen Q, Zonghuan L, Xiang H. Inhibition of hypoxia-inducible factor-1 alpha radiosensitized MG-63 human osteosarcoma cells in vitro. Tumori J. 2015;101(5):578–84. https://doi.org/10.5301/tj.5000243.CrossRef

257.

Staab A, Loeffler J, Said HM, Diehlmann D, Katzer A, Beyer M, et al. Effects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells. BMC Cancer. 2007;7(1):213. https://doi.org/10.1186/1471-2407-7-213.CrossRefPubMedPubMedCentral

258.

Kessler J, Hahnel A, Wichmann H, Rot S, Kappler M, Bache M, et al. HIF-1α inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression. BMC Cancer. 2010;10(1):605. https://doi.org/10.1186/1471-2407-10-605.CrossRefPubMedPubMedCentral

259.

Min S, Wang X, Du Q, Gong H, Yang Y, Wang T, et al. Chetomin, a Hsp90/HIF1α pathway inhibitor, effectively targets lung cancer stem cells and non-stem cells. Cancer Biol Ther. 2020;21(8):1–11. https://doi.org/10.1080/15384047.2020.1763147.CrossRef

260.

DiGiacomo JW, Gilkes DM. Therapeutic strategies to block the hypoxic response. In: Gilkes DM, editor. Hypoxia cancer metastasis. Cham: Springer International Publishing; 2019. p. 141–57. https://doi.org/10.1007/978-3-030-12734-3_10.CrossRef

261.

Li Z, You Q, Zhang X. Small-molecule modulators of the hypoxia-inducible factor pathway: Development and therapeutic applications. J Med Chem. 2019;62(12):5725–49. https://doi.org/10.1021/acs.jmedchem.8b01596.CrossRefPubMed

262.

Courtney KD, Ma Y, de Leon AD, Christie A, Xie Z, Woolford L, et al. HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma. Clin Cancer Res. 2020;26(4):793–803. https://doi.org/10.1158/1078-0432.CCR-19-1459.CrossRefPubMed

263.

Bhatt RS, Landis DM, Zimmer M, Torregrossa J, Chen S, Sukhatme VP, et al. Hypoxia-inducible factor-2α: effect on radiation sensitivity and differential regulation by an mTOR inhibitor. BJU Int. 2008;102(3):358–63. https://doi.org/10.1111/j.1464-410X.2008.07558.x.CrossRefPubMedPubMedCentral

264.

Bertout JA, Majmundar AJ, Gordan JD, Lam JC, Ditsworth D, Keith B, et al. HIF2α inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proc Natl Acad Sci. 2009;106(34):14391–6. https://doi.org/10.1073/pnas.0907357106.CrossRefPubMedPubMedCentral

265.

Zhou J, Wu K, Gao D, Zhu G, Wu D, Wang X, et al. Reciprocal regulation of hypoxia-inducible factor 2α and GLI1 expression associated with the radioresistance of renal cell carcinoma. Int J Radiat Oncol. 2014;90(4):942–51. https://doi.org/10.1016/j.ijrobp.2014.06.065.CrossRef

266.

Pietras A, Katz AM, Ekström EJ, Wee B, Halliday JJ, Pitter KL, et al. Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell. 2014;14(3):357–69. https://doi.org/10.1016/j.stem.2014.01.005.CrossRefPubMedPubMedCentral

267.

Zhao J, Du F, Luo Y, Shen G, Zheng F, Xu B. The emerging role of hypoxia-inducible factor-2 involved in chemo/radioresistance in solid tumors. Cancer Treat Rev. 2015;41(7):623–33. https://doi.org/10.1016/j.ctrv.2015.05.004.CrossRefPubMed

268.

Zu XL, Guppy M. Cancer metabolism: facts, fantasy, and fiction. Biochem Biophys Res Commun. 2004;313(3):459–65. https://doi.org/10.1016/j.bbrc.2003.11.136.CrossRefPubMed

269.

Coates JT, Skwarski M, Higgins GS. Targeting tumour hypoxia: shifting focus from oxygen supply to demand. Br J Radiol. 2018;92:20170843. https://doi.org/10.1259/bjr.20170843.CrossRefPubMedPubMedCentral

270.

Kery M, Papandreou I. Emerging strategies to target cancer metabolism and improve radiation therapy outcomes. Br J Radiol. 2020;20200067(1115):20200067. https://doi.org/10.1259/bjr.20200067.CrossRef

271.

Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med. 2011;9(1):33. https://doi.org/10.1186/1741-7015-9-33.CrossRefPubMedPubMedCentral

272.

Zannella VE, Dal Pra A, Muaddi H, McKee TD, Stapleton S, Sykes J, et al. Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin Cancer Res. 2013;19(24):6741–50. https://doi.org/10.1158/1078-0432.CCR-13-1787.CrossRefPubMed

273.

Farhadi P, Yarani R, Dokaneheifard S, Mansouri K. The emerging role of targeting cancer metabolism for cancer therapy. Tumor Biol. 2020;42(10):1010428320965284. https://doi.org/10.1177/1010428320965284.CrossRef

274.

Kurelac I, Iommarini L, Vatrinet R, Amato LB, De Luise M, Leone G, et al. Inducing cancer indolence by targeting mitochondrial Complex I is potentiated by blocking macrophage-mediated adaptive responses. Nat Commun. 2019;10(1):903. https://doi.org/10.1038/s41467-019-08839-1.CrossRefPubMedPubMedCentral

275.

Wink KCJ, Belderbos JSA, Dieleman EMT, Rossi M, Rasch CRN, Damhuis RAM, et al. Improved progression free survival for patients with diabetes and locally advanced non-small cell lung cancer (NSCLC) using metformin during concurrent chemoradiotherapy. Radiother Oncol. 2016;118(3):453–9. https://doi.org/10.1016/j.radonc.2016.01.012.CrossRefPubMed

276.

Fiorillo M, Lamb R, Tanowitz HB, Mutti L, Krstic-Demonacos M, Cappello AR, et al. Repurposing atovaquone: Targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells. Oncotarget. 2016;7(23):34084–99. https://doi.org/10.18632/oncotarget.9122.CrossRefPubMedPubMedCentral

277.

Ashton TM, Fokas E, Kunz-Schughart LA, Folkes LK, Anbalagan S, Huether M, et al. The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia. Nat Commun. 2016;7(1):12308. https://doi.org/10.1038/ncomms12308.CrossRefPubMedPubMedCentral

278.

Benej M, Hong X, Vibhute S, Scott S, Wu J, Graves E, et al. Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism. Proc Natl Acad Sci U S A. 2018;115(42):10756–61. https://doi.org/10.1073/pnas.1808945115.CrossRefPubMedPubMedCentral

279.

Diepart C, Karroum O, Magat J, Feron O, Verrax J, Calderon PB, et al. Arsenic trioxide treatment decreases the oxygen consumption rate of tumor cells and radiosensitizes solid tumors. Cancer Res. 2012;72(2):482–90. https://doi.org/10.1158/0008-5472.CAN-11-1755.CrossRefPubMed

280.

Fang Y, Zhang Z. Arsenic trioxide as a novel anti-glioma drug: a review. Cell Mol Biol Lett. 2020;25(1):44. https://doi.org/10.1186/s11658-020-00236-7.CrossRefPubMedPubMedCentral

281.

Crokart N, Radermacher K, Jordan BF, Baudelet C, Cron GO, Grégoire V, et al. Tumor radiosensitization by antiinflammatory drugs: Evidence for a new mechanism involving the oxygen effect. Cancer Res. 2005;65(17):7911–6. https://doi.org/10.1158/0008-5472.CAN-05-1288.CrossRefPubMed

282.

Crokart N, Jordan BF, Baudelet C, Cron GO, Hotton J, Radermacher K, et al. Glucocorticoids modulate tumor radiation response through a decrease in tumor oxygen consumption. Clin Cancer Res. 2007;13(2):630–5. https://doi.org/10.1158/1078-0432.CCR-06-0802.CrossRefPubMed

283.

Ellinghaus P, Heisler I, Unterschemmann K, Haerter M, Beck H, Greschat S, et al. BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I. Cancer Med. 2013;2(5):611–24. https://doi.org/10.1002/cam4.112.CrossRefPubMedPubMedCentral

284.

Schöckel L, Glasauer A, Basit F, Bitschar K, Truong H, Erdmann G, et al. Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth. Cancer Metab. 2015;3(1):11. https://doi.org/10.1186/s40170-015-0138-0.CrossRefPubMedPubMedCentral

285.

Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med. 2018;24(7):1036–46. https://doi.org/10.1038/s41591-018-0052-4.CrossRefPubMed

286.

Helbig L, Koi L, Brüchner K, Gurtner K, Hess-Stumpp H, Unterschemmann K, et al. BAY 87–2243, a novel inhibitor of hypoxia-induced gene activation, improves local tumor control after fractionated irradiation in a schedule-dependent manner in head and neck human xenografts. Radiat Oncol. 2014;9(1):207. https://doi.org/10.1186/1748-717X-9-207.CrossRefPubMedPubMedCentral

287.

Chen D, Barsoumian HB, Fischer G, Yang L, Verma V, Younes AI, et al. Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity. J Immunother Cancer. 2020;8(1):e000289. https://doi.org/10.1136/jitc-2019-000289.CrossRefPubMedPubMedCentral

288.

Abla H, Sollazzo M, Gasparre G, Iommarini L, Porcelli AM. The multifaceted contribution of α-ketoglutarate to tumor progression: An opportunity to exploit? Semin Cell Dev Biol. 2020;98:26–33. https://doi.org/10.1016/j.semcdb.2019.05.031.CrossRefPubMed

289.

Wahl D, Petronek M, Ramachandran R, Floberg J, Allen BG, Schwarz JK. Targeting tumor metabolism to overcome radioresistance. In: Willers H, Eke I, editors. Molecular targeted radiosensitizers: opportunities and challenges. Cham: Springer International Publishing; 2020. p. 219–63. https://doi.org/10.1007/978-3-030-49701-9_10.CrossRef

290.

Oleson JR. Eugene Robertson Special Lecture: Hyperthermia from the clinic to the laboratory: A hypothesis. Int J Hyperth. 1995;11(3):315–22. https://doi.org/10.3109/02656739509022467.CrossRef

291.

Vaupel PW, Kelleher DK. Pathophysiological and vascular characteristics of tumours and their importance for hyperthermia: Heterogeneity is the key issue. Int J Hyperth. 2010;26(3):211–23. https://doi.org/10.3109/02656731003596259.CrossRef

292.

El-Awady RA, Dikomey E, Dahm-Daphi J. Heat effects on DNA repair after ionising radiation: hyperthermia commonly increases the number of non-repaired double-strand breaks and structural rearrangements. Nucleic Acids Res. 2001;29(9):1960–6. https://doi.org/10.1093/nar/29.9.1960.CrossRefPubMedPubMedCentral

293.

Ihara M, Takeshita S, Okaichi K, Okumura Y, Ohnishi T. Heat exposure enhances radiosensitivity by depressing DNA-PK kinase activity during double strand break repair. Int J Hyperth Off J Eur Soc Hyperthermic Oncol North Am Hyperth Group. 2014;30(2):102–9. https://doi.org/10.3109/02656736.2014.887793.CrossRef

294.

Krawczyk PM, Eppink B, Essers J, Stap J, Rodermond H, Odijk H, et al. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc Natl Acad Sci U S A. 2011;108(24):9851–6. https://doi.org/10.1073/pnas.1101053108.CrossRefPubMedPubMedCentral

295.

Oei AL, Vriend LEM, Crezee J, Franken NAP, Krawczyk PM. Effects of hyperthermia on DNA repair pathways: one treatment to inhibit them all. Radiat Oncol. 2015;10(1):165. https://doi.org/10.1186/s13014-015-0462-0.CrossRefPubMedPubMedCentral

296.

Schaaf L, Schwab M, Ulmer C, Heine S, Mürdter TE, Schmid JO, et al. Hyperthermia synergizes with chemotherapy by inhibiting PARP1-dependent DNA replication arrest. Cancer Res. 2016;76(10):2868–75. https://doi.org/10.1158/0008-5472.CAN-15-2908.CrossRefPubMed

297.

van den Tempel N, Laffeber C, Odijk H, van Cappellen WA, van Rhoon GC, Franckena M, et al. The effect of thermal dose on hyperthermia-mediated inhibition of DNA repair through homologous recombination. Oncotarget. 2017;8(27):44593–604. https://doi.org/10.18632/oncotarget.17861.CrossRefPubMedPubMedCentral

298.

Zhao Y-Y, Wu Q, Wu Z-B, Zhang J-J, Zhu L-C, Yang Y, et al. Microwave hyperthermia promotes caspase-3-dependent apoptosis and induces G2/M checkpoint arrest via the ATM pathway in non-small cell lung cancer cells. Int J Oncol. 2018;53:539–50. https://doi.org/10.3892/ijo.2018.4439.CrossRefPubMedPubMedCentral

299.

Harmon BV, Corder AM, Collins RJ, Gobé GC, Allen J, Allan DJ, et al. Cell death induced in a murine mastocytoma by 42–47°C heating in vitro: Evidence that the form of death changes from apoptosis to necrosis above a critical heat load. Int J Radiat Biol. 1990;58(5):845–58. https://doi.org/10.1080/09553009014552221.CrossRefPubMed

300.

Kampinga HH. Thermotolerance in mammalian cells. Protein denaturation and aggregation, and stress proteins. J Cell Sci. 1993;104(1):11–7. https://doi.org/10.1242/jcs.104.1.11.CrossRefPubMed

301.

Vertrees RA, Das GC, Coscio AM, Xie J, Zwischenberger JB, Boor PJ. A mechanism of hyperthermia-induced apoptosis in ras-transformed lung cells. Mol Carcinog. 2005;44(2):111–21. https://doi.org/10.1002/mc.20124.CrossRefPubMed

302.

Song CW. Effect of local hyperthermia on blood flow and microenvironment: A review. Cancer Res. 1984;44:4721s–30s.PubMed

303.

Sadeghi N, Kok RJ, Bos C, Zandvliet M, Geerts WJC, Storm G, et al. Hyperthermia-triggered release of hypoxic cell radiosensitizers from temperature-sensitive liposomes improves radiotherapy efficacy in vitro. Nanotechnology. 2019;30(26):264001. https://doi.org/10.1088/1361-6528/ab0ce6.CrossRefPubMed

304.

Murata R, Nishimura Y, Hiraoka M. An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int J Radiat Oncol Biol Phys. 1997;37(5):1107–13. https://doi.org/10.1016/s0360-3016(96)00628-1.CrossRefPubMed

305.

Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature. 1998;394(6690):287–91. https://doi.org/10.1038/28412.CrossRefPubMed

306.

Teicher BA, Holden SA, Ara G, Dupuis NP, Liu F, Yuan J, et al. Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy. Int J Cancer. 1995;61(5):732–7. https://doi.org/10.1002/ijc.2910610523.CrossRefPubMed

307.

Teicher BA, Dupuis N, Kusomoto T, Robinson MF, Liu F, Menon K, et al. Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiat Oncol Investig. 1994;2(6):269–76. https://doi.org/10.1002/roi.2970020604.CrossRef

308.

Gorski DH, Mauceri HJ, Salloum RM, Gately S, Hellman S, Beckett MA, et al. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res. 1998;58(24):5686–9.PubMed

309.

Hess C, Vuong V, Hegyi I, Riesterer O, Wood J, Fabbro D, et al. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer. 2001;85(12):2010–6. https://doi.org/10.1054/bjoc.2001.2166.CrossRefPubMedPubMedCentral

310.

Riesterer O, Honer M, Jochum W, Oehler C, Ametamey S, Pruschy M. Ionizing radiation antagonizes tumor hypoxia induced by antiangiogenic treatment. Clin Cancer Res. 2006;12(11):3518–24. https://doi.org/10.1158/1078-0432.CCR-05-2816.CrossRefPubMed

311.

Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med. 2001;7(9):987–9. https://doi.org/10.1038/nm0901-987.CrossRefPubMed

312.

Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58–62. https://doi.org/10.1126/science.1104819.CrossRefPubMed

313.

Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011;10(6):417–27. https://doi.org/10.1038/nrd3455.CrossRefPubMed

314.

Kleibeuker EA, Griffioen AW, Verheul HM, Slotman BJ, Thijssen VL. Combining angiogenesis inhibition and radiotherapy: A double-edged sword. Drug Resist Updat. 2012;15(3):173–82. https://doi.org/10.1016/j.drup.2012.04.002.CrossRefPubMed

315.

Mazeron R, Anderson B, Supiot S, Paris F, Deutsch E. Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy. Cancer Treat Rev. 2011;37:476–86. https://doi.org/10.1016/j.ctrv.2011.03.004.CrossRefPubMed

316.

Goedegebuure RSA, de Klerk LK, Bass AJ, Derks S, Thijssen VLJL. Combining radiotherapy with anti-angiogenic therapy and immunotherapy; A therapeutic triad for cancer? Front Immunol. 2019;9:3107. https://doi.org/10.3389/fimmu.2018.03107.CrossRefPubMedPubMedCentral

317.

Batchelor TT, Sorensen AG, di Tomaso E, Zhang W-T, Duda DG, Cohen KS, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11(1):83–95. https://doi.org/10.1016/j.ccr.2006.11.021.CrossRefPubMedPubMedCentral

318.

Dings RPM, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, et al. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res. 2007;13(11):3395–402. https://doi.org/10.1158/1078-0432.CCR-06-2441.CrossRefPubMedPubMedCentral

319.

Oehler-Jänne C, Jochum W, Riesterer O, Broggini-Tenzer A, Caravatti G, Vuong V, et al. Hypoxia modulation and radiosensitization by the novel dual EGFR and VEGFR inhibitor AEE788 in spontaneous and related allograft tumor models. Mol Cancer Ther. 2007;6(9):2496–504. https://doi.org/10.1158/1535-7163.MCT-07-0253.CrossRefPubMed

320.

Winkler F, Kozin SV, Tong RT, Chae S-S, Booth MF, Garkavtsev I, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004;6(6):553–63. https://doi.org/10.1016/j.ccr.2004.10.011.CrossRefPubMed

321.

Kleibeuker EA, Ten Hooven MA, Castricum KC, Honeywell R, Griffioen AW, Verheul HM, et al. Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction. Cancer Med. 2015;4(7):1003–15. https://doi.org/10.1002/cam4.441.CrossRefPubMedPubMedCentral

322.

Hamming LC, Slotman BJ, Verheul HMW, Thijssen VL. The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future. Angiogenesis. 2017;20(2):217–32. https://doi.org/10.1007/s10456-017-9546-9.CrossRefPubMedPubMedCentral

323.

Kazimova T, Tschanz F, Sharma A, Telarovic I, Wachtel M, Pedot G, et al. Paracrine placental growth factor signaling in response to ionizing radiation is p53-dependent and contributes to radioresistance. Mol Cancer Res. 2021;19(6):1051–62. https://doi.org/10.1158/1541-7786.MCR-20-0403.CrossRefPubMed

324.

Fokas E, Im JH, Hill S, Yameen S, Stratford M, Beech J, et al. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res. 2012;72(1):239–48. https://doi.org/10.1158/0008-5472.CAN-11-2263.CrossRefPubMed

325.

Qayum N, Muschel RJ, Im JH, Balathasan L, Koch CJ, Patel S, et al. Tumor vascular changes mediated by inhibition of oncogenic signaling. Cancer Res. 2009;69(15):6347–54. https://doi.org/10.1158/0008-5472.CAN-09-0657.CrossRefPubMedPubMedCentral

326.

Matsumoto S, Batra S, Saito K, Yasui H, Choudhuri R, Gadisetti C, et al. Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia. Cancer Res. 2011;71(20):6350–9. https://doi.org/10.1158/0008-5472.CAN-11-2025.CrossRefPubMedPubMedCentral

327.

Riesterer O, Oehler-Jänne C, Jochum W, Broggini-Tenzer A, Vuong V, Pruschy M. Ionizing radiation and inhibition of angiogenesis in a spontaneous mammary carcinoma and in a syngenic heterotopic allograft tumor model: a comparative study. Radiat Oncol. 2011;6(1):66. https://doi.org/10.1186/1748-717X-6-66.CrossRefPubMedPubMedCentral

328.

Wachsberger PR, Burd R, Marero N, Daskalakis C, Ryan A, McCue P, et al. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res. 2005;11(2 Pt 1):835–42.PubMed

329.

Zips D, Krause M, Hessel F, Westphal J, Brüchner K, Eicheler W, et al. Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation. Anticancer Res. 2003;23(5A):3869–76.PubMed

330.

Hlushchuk R, Riesterer O, Baum O, Wood J, Gruber G, Pruschy M, et al. Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation. Am J Pathol. 2008;173(4):1173–85. https://doi.org/10.2353/ajpath.2008.071131.CrossRefPubMedPubMedCentral

331.

Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest. 2010;120(3):694–705. https://doi.org/10.1172/JCI40283.CrossRefPubMedPubMedCentral

332.

Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003;300(5622):1155–9. https://doi.org/10.1126/science.1082504.CrossRefPubMed

333.

Albert JM, Cao C, Geng L, Leavitt L, Hallahan DE, Lu B. Integrin alpha v beta 3 antagonist cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. Int J Radiat Oncol Biol Phys. 2006;65(5):1536–43. https://doi.org/10.1016/j.ijrobp.2006.04.036.CrossRefPubMed

334.

Cuneo KC, Geng L, Tan J, Brousal J, Shinohara ET, Osusky K, et al. SRC family kinase inhibitor SU6656 enhances antiangiogenic effect of irradiation. Int J Radiat Oncol Biol Phys. 2006;64(4):1197–203. https://doi.org/10.1016/j.ijrobp.2005.11.014.CrossRefPubMed

335.

Truman J-P, García-Barros M, Kaag M, Hambardzumyan D, Stancevic B, Chan M, et al. Endothelial membrane remodeling is obligate for anti-angiogenic radiosensitization during tumor radiosurgery. PLoS One. 2010;5(8):e12310. https://doi.org/10.1371/journal.pone.0012310.CrossRefPubMedPubMedCentral

336.

Overgaard J. Sensitization of hypoxic tumour cells - Clinical experience. Int J Radiat Biol. 1989;56(5):801–11. https://doi.org/10.1080/09553008914552081.CrossRefPubMed

337.

Hoff CM. Importance of hemoglobin concentration and its modification for the outcome of head and neck cancer patients treated with radiotherapy. Acta Oncol Stockh Swed. 2012;51(4):419–32. https://doi.org/10.3109/0284186X.2011.653438.CrossRef

338.

Belenkov AI, Shenouda G, Rizhevskaya E, Cournoyer D, Belzile J-P, Souhami L, et al. Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Mol Cancer Ther. 2004;3(12):1525–32.PubMed

339.

Machtay M, Pajak TF, Suntharalingam M, Shenouda G, Hershock D, Stripp DC, et al. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). Int J Radiat Oncol Biol Phys. 2007;69(4):1008–17. https://doi.org/10.1016/j.ijrobp.2007.04.063.CrossRefPubMed

340.

Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinom. J Clin Oncol. 2010;28(33):4912–8. https://doi.org/10.1200/JCO.2010.28.4950.CrossRefPubMed

341.

Song YP, Mistry H, Choudhury A, Hoskin P. Long-term outcomes of hypoxia modification in bladder preservation: Update from BCON trial. J Clin Oncol. 2019;37(7_suppl):356. https://doi.org/10.1200/JCO.2019.37.7_suppl.356.CrossRef

342.

Kaanders JHAM, Bussink J, van der Kogel AJ. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol. 2002;3(12):728–37. https://doi.org/10.1016/s1470-2045(02)00929-4.CrossRefPubMed

343.

Janssens GO, Rademakers SE, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P, et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J Clin Oncol. 2012;30(15):1777–83. https://doi.org/10.1200/JCO.2011.35.9315.CrossRefPubMed

344.

Janssens GO, Langendijk JA, Terhaard CH, Doornaert PA, van den Ende P, de Jong MA, et al. Quality-of-life after radiotherapy for advanced laryngeal cancer: Results of a phase III trial of the Dutch Head and Neck Society. Radiother Oncol. 2016;119(2):213–20. https://doi.org/10.1016/j.radonc.2016.02.023.CrossRefPubMed

345.

Suh JH, Stea B, Tankel K, Marsiglia H, Belkacemi Y, Gomez H, et al. Results of the phase III ENRICH (RT-016) study of efaproxiral administered concurrent with whole brain radiation therapy (WBRT) in women with brain metastases from breast cancer. Int J Radiat Oncol Biol Phys. 2008;72(1):S50–1. https://doi.org/10.1016/j.ijrobp.2008.06.880.CrossRef

346.

Gainer JL, Sheehan JP, Larner JM, Jones DR. Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme. J Neurosurg. 2017;126(2):460–6. https://doi.org/10.3171/2016.3.JNS152693.CrossRefPubMed

347.

Johnson JLH, Dolezal MC, Kerschen A, Matsunaga TO, Unger EC. In Vitro comparison of dodecafluoropentane (DDFP), perfluorodecalin (PFD), and perfluoroctylbromide (PFOB) in the facilitation of oxygen exchange. Artif Cells Blood Substit Biotechnol. 2009;37(4):156–62. https://doi.org/10.1080/10731190903043192.CrossRef

348.

Graham K, Unger E. Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment. Int J Nanomedicine. 2018;13:6049–58. https://doi.org/10.2147/IJN.S140462.CrossRefPubMedPubMedCentral

349.

Limani P, Linecker M, Schneider MA, Kron P, Tschuor C, Kachaylo E, et al. The allosteric hemoglobin effector ITPP inhibits metastatic colon cancer in mice. Ann Surg. 2017;266(5):746–53. https://doi.org/10.1097/SLA.0000000000002431.CrossRefPubMed

350.

Iyengar S, Schwartz D. Failure of inositol trispyrophosphate to enhance highly effective radiotherapy of GL261 glioblastoma in mice. Anticancer Res. 2017;37(3):1121–5. https://doi.org/10.21873/anticanres.11425.CrossRefPubMed

351.

Tran L-B, Cao-Pham T-T, Jordan BF, Deschoemaeker S, Heyerick A, Gallez B. Impact of myo-inositol trispyrophosphate (ITPP) on tumour oxygenation and response to irradiation in rodent tumour models. J Cell Mol Med. 2019;23(3):1908–16. https://doi.org/10.1111/jcmm.14092.CrossRefPubMed

352.

Grgic I, Tschanz F, Borgeaud N, Gupta A, Clavien P-A, Guckenberger M, et al. Tumor oxygenation by myo-inositol trispyrophosphate enhances radiation response. Int J Radiat Oncol. 2021; https://doi.org/10.1016/j.ijrobp.2021.02.012.

353.

Teoh M, Clark CH, Wood K, Whitaker S, Nisbet A. Volumetric modulated arc therapy: a review of current literature and clinical use in practice. Br J Radiol. 2011;84(1007):967–96. https://doi.org/10.1259/bjr/22373346.CrossRefPubMedPubMedCentral

354.

Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S, et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys. 2000;47(3):551–60. https://doi.org/10.1016/s0360-3016(00)00467-3.CrossRefPubMed

355.

Nehmeh SA, Lee NY, Schröder H, Squire O, Zanzonico PB, Erdi YE, et al. Reproducibility of intratumor distribution of 18F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):235–42. https://doi.org/10.1016/j.ijrobp.2007.08.036.CrossRefPubMedPubMedCentral

356.

Vera P, Thureau S, Chaumet-Riffaud P, Modzelewski R, Bohn P, Vermandel M, et al. Phase II Study of a radiotherapy total dose increase in hypoxic lesions identified by 18F-misonidazole PET/CT in patients with non-small cell lung carcinoma (RTEP5 study). J Nucl Med Off Publ Soc Nucl Med. 2017;58(7):1045–53. https://doi.org/10.2967/jnumed.116.188367.CrossRef

357.

Vera P, Mihailescu S-D, Lequesne J, Modzelewski R, Bohn P, Hapdey S, et al. Radiotherapy boost in patients with hypoxic lesions identified by 18F-FMISO PET/CT in non-small-cell lung carcinoma: can we expect a better survival outcome without toxicity? [RTEP5 long-term follow-up]. Eur J Nucl Med Mol Imaging. 2019;46(7):1448–56. https://doi.org/10.1007/s00259-019-04285-9.CrossRefPubMed

358.

Welz S, Mönnich D, Pfannenberg C, Nikolaou K, Reimold M, La Fougère C, et al. Prognostic value of dynamic hypoxia PET in head and neck cancer: Results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial. Radiother Oncol. 2017;124(3):526–32. https://doi.org/10.1016/j.radonc.2017.04.004.CrossRefPubMed

359.

Tubin S, Raunik W. Hunting for abscopal and bystander effects: clinical exploitation of non-targeted effects induced by partial high-single-dose irradiation of the hypoxic tumour segment in oligometastatic patients. Acta Oncol. 2017;56(10):1333–9. https://doi.org/10.1080/0284186X.2017.1346385.CrossRefPubMed

360.

Tubin S, Popper HH, Brcic L. Novel stereotactic body radiation therapy (SBRT)-based partial tumor irradiation targeting hypoxic segment of bulky tumors (SBRT-PATHY): improvement of the radiotherapy outcome by exploiting the bystander and abscopal effects. Radiat Oncol. 2019;14(1):21. https://doi.org/10.1186/s13014-019-1227-y.CrossRefPubMedPubMedCentral

361.

Tubin S, Ahmed MM, Gupta S. Radiation and hypoxia-induced non-targeted effects in normoxic and hypoxic conditions in human lung cancer cells. Int J Radiat Biol. 2018;94(3):199–211. https://doi.org/10.1080/09553002.2018.1422085.CrossRefPubMed

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Interfering with Tumor Hypoxia for Radiotherapy Optimization

Abstract

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Chemoresistance is mediated by ovarian cancer leader cells in vitro

Correction to: Short hairpin RNA- mediated gene knockdown of FOXM1 inhibits the proliferation and metastasis of human colon cancer cells through reversal of epithelial-to-mesenchymal transformation

What are the applications of single-cell RNA sequencing in cancer research: a systematic review

Correction to: A novel miR-219-SMC4-JAK2/Stat3 regulatory pathway in human hepatocellular carcinoma

NOX1 inhibition attenuates the development of a pro‐tumorigenic environment in experimental hepatocellular carcinoma

Correction to: Cancer-associated fibroblasts promote the survival of irradiated nasopharyngeal carcinoma cells via the NF-κB pathway

Keynote webinar | Spotlight on antibody–drug conjugates in cancer